Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Asciminib Hydrochloride in Chronic phase chronic myeloid leukemia: NCT07604233 Clinical Landscape Report 2026
16 September 2026
NCT07604233 clinical landscape for Chronic phase chronic myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Anlotinib Dihydrochloride in Locally Advanced Clear Cell Renal Cell Carcinoma: NCT07602101 Clinical Landscape Report 2026
16 September 2026
NCT07602101 clinical landscape for Locally Advanced Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Lisaftoclax in Diffuse large B-cell lymphoma refractory: NCT07601607 Clinical Landscape Report 2026
16 September 2026
NCT07601607 clinical landscape for Diffuse large B-cell lymphoma refractory: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Iberdomide in Extramedullary Disease in Multiple Myeloma: NCT07601100 Clinical Landscape Report 2026
16 September 2026
NCT07601100 clinical landscape for Extramedullary Disease in Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Tocilizumab in Multiple Myeloma: NCT07609940 Clinical Landscape Report 2026
16 September 2026
NCT07609940 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
MK-4884 in Solid tumor: NCT07600749 Clinical Landscape Report 2026
16 September 2026
NCT07600749 clinical landscape for Solid tumor: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ocrelizumab biosimilar(Polpharma Biologics) in Multiple Sclerosis, Primary Progressive: NCT07606521 Clinical Landscape Report 2026
16 September 2026
NCT07606521 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Rocbrutinib in Mantle-Cell Lymphoma: NCT07609862 Clinical Landscape Report 2026
16 September 2026
NCT07609862 clinical landscape for Mantle-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ocrelizumab in Multiple Sclerosis: NCT07609719 Clinical Landscape Report 2026
16 September 2026
NCT07609719 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Belantamab mafodotin in Hepatic Insufficiency: NCT07609706 Clinical Landscape Report 2026
16 September 2026
NCT07609706 clinical landscape for Hepatic Insufficiency: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pemetrexed Dipotassium in Large B-cell lymphoma: NCT07608731 Clinical Landscape Report 2026
16 September 2026
NCT07608731 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ABBV-519 in Rheumatoid Arthritis: NCT07607964 Clinical Landscape Report 2026
16 September 2026
NCT07607964 clinical landscape for Rheumatoid Arthritis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.